Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases

Documenti analoghi

• Epithelial-Mesenchymal Transition Markers and HER3 Expression Are Predictors of Elisidepsin Treatment Response in Breast and Pancreatic Cancer Cell Lines
  di: Teixidó, Cristina, et al.
  Pubblicazione: (2013)
• Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle
  di: De Mattos-Arruda, L, et al.
  Pubblicazione: (2014)
• Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle
  di: Mattos-Arruda, L De, et al.
  Pubblicazione: (2018)
• Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing
  di: De Mattos-Arruda, Leticia, et al.
  Pubblicazione: (2013)
• MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients
  di: De Mattos-Arruda, Leticia, et al.
  Pubblicazione: (2015)